Moderna is now touting that its vaccine is 96% effective in teens ages 12-17.
The drug maker recently announced the results of its Phase 2 trial in reporting for their first-quarter earnings. The vaccine has already generated $1.7 billion in revenue in its fiscal first quarter.
Moderna’s announcement also comes just as rival drug maker, Pfizer, is set to receive federal authorization to use its COVID-19 vaccine in adolescents early next week.
Federal approval of the vaccines against COVID-19 could finally enable many middle and high school students in the U.S to be vaccinated in time to start the 2021-22 school year.
